Aims/hypothesis Polycystic ovary syndrome (PCOS) is a multifaceted metabolic disease linked with insulin resistance (IR) and obesity. Adiponectin, which is lower in IR states, exerts its glucose-lowering and anti-inflammatory effects by activating two receptors, ADIPOR1 and ADI-POR2. There are no data on the relative expression of these receptors in adipose tissue of PCOS women. Methods We investigated the expression of adiponectin receptors from corresponding s.c. and omental (o.m.) adipose tissue in women with PCOS compared with matched non-PCOS women. As there is a disturbance in the steroid milieu in PCOS women, we also assessed the effects of testosterone and oestradiol on adiponectin receptors using adipocytes and adipocyte explants. Realtime RT-PCR and western blotting were used to assess the relative adiponectin receptor mRNA expression and protein production, respectively. Biochemical measurements were performed in our hospital's laboratory. Results We are the first to describe adiponectin receptor expression and production, in corresponding s.c. and o.m. human adipose tissues at the mRNA and protein level. We demonstrate the upregulation of mRNA expression and protein production of adiponectin receptors in women with PCOS, in s.c. and o.m. adipose tissue. Treatment of adipose tissue explants and adipocytes with testosterone and oestradiol induced the expression of adiponectin receptor mRNA and protein. There was a significant positive association between ADIPOR1/R2 expression and homeostasis model assessment, testosterone, oestradiol and triglycerides and a negative relationship with sex hormonebinding globulin. Conclusions/interpretation The precise reason for the upregulation of adiponectin receptors seen in PCOS women, a pro-diabetic state, is unknown, but it appears that sex steroids may play a role in their regulation in adipose tissue. 
Introduction
Polycystic ovary syndrome (PCOS) is characterised by menstrual dysregulation and hyperandrogenism, and is associated with hyperinsulinaemia [1] ; it is a multifaceted metabolic disease with dyslipidaemia, overt type 2 diabetes mellitus, insulin resistance (IR) and visceral obesity being more prevalent than in weight-matched control subjects [1, 2] .
Adiponectin, which is lower in insulin-resistant states [3] , orchestrates its glucose-lowering and anti-inflammatory effects by activating two membrane receptors, adiponectin receptor-1 (ADIPOR1) and adiponectin receptor-2 (ADI-POR2) [4] . These receptors mediate paracrine effects of adiponectin in adipose tissue [5] .
Therefore, given that PCOS is a pro-diabetic and pro-inflammatory state [6] , with a higher prevalence of obesity [6] , we sought to investigate the expression of adiponectin receptors from adipose tissue, both s.c. and omental (o.m.), in women with PCOS compared with matched non-PCOS women. As there is a disturbance in the steroid milieu in PCOS women, we assessed the effects of sex steroids on adiponectin receptors in adipose tissue and adipocytes.
Subjects and methods
After an overnight fast, blood samples and abdominal s.c. and o.m. adipose tissue were obtained (08.00-10.00 h) from adult female patients undergoing elective surgery for infertility investigation. All samples were obtained during the early follicular phase (days 2-4 from the first day of spontaneous bleeding episode); serum/plasma were immediately aliquoted on ice and stored at −80°C (see Electronic supplementary material [ESM] ). The control group had no discernible cause for infertility (unexplained infertility). Equal numbers of women (n=8) were recruited in each group, one that consisted of women with PCOS and the other healthy control subjects (ESM Table 1 ). The local research ethics committee approved the study and all patients involved gave their informed consent, in accordance with the guidelines in The Declaration of Helsinki 2000.
Our PCOS women met all three diagnostic criteria as per the revised 2003 Rotterdam ESHRE/ASRM PCOS Consensus Workshop Group ( [7] ; see ESM).
Biochemical and hormonal analysis Assays for covariates (ESM Table 1 ), were performed using an automated analyser (Abbott Architect; Abbott Laboratories, Abbott Park, IL, USA). Adiponectin was measured by commercial RIA (Linco Research, St Charles, MO, USA). The intraassay variation was 5.7%. The estimate of IR by homeostasis model assessment (HOMA) score was calculated as previously described [8] .
Primary explant culture Adipose tissue organ explants were cultured using methods described by Fried and Moustaid-Moussa ( [9] ; see ESM).
Isolation of primary adipocytes Adipocytes were isolated as previously described [10] . Briefly, adipose tissue was exposed to collagenase digestion (Hanks' Balanced Salt Solution containing 3 mg/ml collagenase [type II] and 1.5% BSA) in a shaking water bath at 37°C for 1 h. Mature adipocytes were separated from the stromal vascular cells through an inert oil, bis(3,5,5 trimethylhexyl) phthalate (Fluka Chemicals, Gillingham, UK).
Total RNA extraction and cDNA synthesis Total RNA was extracted and reverse transcribed as previously described [11] .
RT-PCR Protocol conditions and quantitative PCR of ADIPOR1 and ADIPOR2 were performed on a Roche Light Cycler system (Roche Molecular Biochemicals, Mannheim, Germany), as previously described ( [11] ; see ESM).
Western blotting Protein lysates were prepared by homogenising adipose tissue in modified radioimmunoprecipitation lysis buffer (Upstate, Lake Placid, NY, USA) according to the manufacturer's instructions, and subjected to western blotting protocol conditions and analysis as previously described by us ( [11] ; see ESM).
Immunohistocytochemistry Adipose tissue sections from subjects were cut at 3 μm and floated onto 3-aminopropyltriethoxy-silane coated slides and immunohistocytochemical analysis was performed as previously described ( [12] ; see ESM).
Statistical analysis Non-parametric tests were used. Differences between two groups were assessed using the MannWhitney U test. Data involving more than two groups were assessed by Kruskal-Wallis and Friedman's ANOVA. For western immunoblotting experiments, the densities were measured using a scanning densitometer coupled to scanning software (ImageQuant; Molecular Dynamics, Amersham Pharmacia, Little Chalfont, UK). Spearman rank correlation was used for calculation of associations between variables. Values are expressed as means±SEM unless indicated otherwise. p<0.05 was considered significant for all analyses.
Results
Clinical, hormonal and metabolic features of subjects are described in ESM Table 1 .
Expression of adiponectin receptor genes in normal and PCOS women There was no significant difference in ADIPOR1/R2 mRNA in either fat depot in normal or PCOS women (Fig. 1a,b) . However, there was significant upregulation of ADIPOR1 and ADIPOR2 in both fat depots of PCOS women (Fig. 1a,b; p<0.05) . Furthermore, significantly higher expression of ADIPOR1 and ADIPOR2 was noted in isolated s.c. adipocytes in PCOS women ( Fig. 1c,d ; p<0.05).
Protein production of adiponectin receptors in normal and PCOS women Western blotting detected significantly greater ADIPOR1 (42 kDa) protein in both s.c. and o.m. adipose tissue of PCOS women ( Fig. 1e; p<0.01 b Fig. 1 a, Fig. 1f; p<0.05). Immunohistocytochemical analysis revealed intense membrane staining for both ADIPOR1 and ADIPOR2 in adipocytes (ESM Fig. 1 ).
Effects of testosterone and 17β-oestradiol (E2) on adiponectin receptor expression and production in isolated human s.c. adipocytes and adipose tissue explants Human s.c. adipocytes treated with testosterone and E2 had significantly increased ADIPOR1 (testosterone: p<0.01; E2: p<0.05) and ADIPOR2 expression (testosterone: p<0.05; E2: p<0.01; Fig. 2a,b) . The effects of testosterone on ADIPOR1/R2 expression were similar in s.c. adipose tissue explants, although with respect to testosterone, ADIPOR1 mRNA was significantly elevated but the increase in ADIPOR2 mRNA failed to reach significance (testosterone: p=NS; E2: p<0.05; Fig. 2c,d ).
Importantly, these mRNA findings were supported by protein data utilising western immunoblotting: ADIPOR1 (testosterone: p<0.01; E2: p<0.01) and ADIPOR2 (testosterone: p<0.01; E2: p<0.01; Fig. 2e,f Effects of testosterone and E2 (100 nmol/l) on ADIPOR1 and ADIPOR2 mRNA in human s.c. adipose tissue explants at 4 h were assessed by real-time RT-PCR, as compared with basal (no supplement); *p<0.05, **p<0.001. e, f Effects of testosterone and E2 (100 nmol/l) on ADIPOR1 and ADIPOR2 protein production as assessed by western blotting in human s.c. adipose tissue explants at 24 h. Densitometric analysis of the immune complexes revealed that there was a significant increase in protein production of ADIPOR1/R2 with both testosterone and E2 when compared with basal (no supplement); *p<0.05, **p<0. 
Discussion
In this short communication, we describe for the first time the expression of adiponectin receptor-1 and -2 in corresponding s.c. and o.m. human adipose tissues at both the mRNA and protein level. Importantly, we present novel data showing the presence and upregulation of ADIPOR1/R2 in both these adipose tissue depots in PCOS women, and the effect of testosterone and E2 on these receptors, these women having a relative excess of these steroids. The precise reasons for our findings need to be determined.
The upregulation of adiponectin receptors in adipose tissue of PCOS women, in whom diabetes is more prevalent, may reflect an increased need for adiponectin receptor signalling and may sensitise the adipocytes to the effects of adiponectin, including its lipolytic activity. Tan et al. [5] showed that as adiponectin receptor mRNA concentrations increased, in vivo postprandial adipose tissue clearance of triglycerides increased. In our study, PCOS women had higher triglyceride levels. It is possible that the increased expression of adiponectin receptors in PCOS women may modulate triglyceride clearance.
Human preadipocytes are capable of active androgen generation [13] . Moreover, adipose tissue aromatises testosterone to E2 locally, which may be pertinent given the hyperandrogenic state in PCOS women. Sex steroids improve insulin sensitivity and decrease risk of diabetes [14] ; however, the precise mechanisms are unclear. Interestingly, we noted significant positive associations between sex steroids and both adiponectin receptors. Furthermore, we provide novel evidence that testosterone and E2 increase adiponectin receptor-1 and -2 mRNA and protein. Therefore, the increased expression and production of adiponectin receptors in PCOS women, with no significant difference in BMI, WHR and plasma adiponectin concentrations compared with control subjects, may be a consequence of the hyperandrogenic state, given the significantly raised testosterone and FAI in PCOS women. However, it is unknown whether these sex steroid effects on adiponectin receptors occur in other tissues.
A limitation of our study may relate to the number of subjects. However, obtaining BMI/WHR-matched and menstrual cycle-synchronised blood and tissue samples impeded subject recruitment. Not withstanding, our observations are highly consistent and significant, and raise interesting questions on the mechanisms regulating adiponectin receptor expression. Moreover, although we present novel data showing that sex steroids influence adiponectin receptor mRNA expression and protein production in adipose tissue, some of our covariate correlations may not have a causative significance, and indeed result from the fact that PCOS is characterised by hyperandrogenism.
In conclusion, we present novel data with increased adiponectin receptors in PCOS adipocytes, and their regulation by sex steroids. The precise mechanisms for our findings remain to be elucidated, but the upregulation of adiponectin receptors may sensitise adipocytes to the effects of adiponectin, and act as a compensatory mechanism by which insulin sensitivity is at least partially restored in these insulin-resistant PCOS women. Future studies, with larger numbers of subjects, should give a better insight into the molecular mechanisms of adiponectin and its receptors in insulin-resistant PCOS women.
